Bepanthen Versus Cetomacrogol in Epidermal Growth Factor Receptor Inhibitors (EGFRI) (BeCet)
|ClinicalTrials.gov Identifier: NCT01136005|
Recruitment Status : Completed
First Posted : June 3, 2010
Last Update Posted : November 13, 2017
CB Boers ORG.
Memorial Sloan Kettering Cancer Center
Leiden University Medical Center
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Primary Completion Date :||December 2016|
|Study Completion Date :||March 2017|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Clabbers JMK, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven KJM, Kaptein AA. Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer. 2016 Feb;24(2):513-521. doi: 10.1007/s00520-015-2781-y. Epub 2015 Jun 27.